Biofrontera Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Biofrontera Inc. (BFRI) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- Biofrontera Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.60M, a 42.24% decline from fiscal 2024.
- Biofrontera Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $4.50M, a 29.69% decline from fiscal 2023.
- Biofrontera Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $6.40M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $2.60M 10-K · filed 2026-03-19 |
| 2024-12-31 | $4.50M 10-K · filed 2026-03-19 |
| 2023-12-31 | $6.40M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |